# A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH

Study · id `cardio:ct-nct03970031` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03970031](<https://clinicaltrials.gov/study/NCT03970031>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03970031

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1800 participants.

## Technical summary

Registry record NCT03970031. Randomized; quadruple masking; primary purpose treatment. Start 2022-06 (anticipated); primary completion 2024-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1800 participants (planned count; ClinicalTrials.gov record NCT03970031, source copy `cardio:ctgov-nct03970031-2021-07-12`, retrieved 2026-10-26)
- Planned start: 2022-06 (anticipated) (ClinicalTrials.gov record NCT03970031, source copy `cardio:ctgov-nct03970031-2021-07-12`, retrieved 2026-10-26)
- Primary completion: 2024-09 (anticipated) (ClinicalTrials.gov record NCT03970031, source copy `cardio:ctgov-nct03970031-2021-07-12`, retrieved 2026-10-26)
- Completion: 2024-09 (anticipated) (ClinicalTrials.gov record NCT03970031, source copy `cardio:ctgov-nct03970031-2021-07-12`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03970031-2021-07-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH
- Condition: Type2 Diabetes
- Condition: NASH - Nonalcoholic Steatohepatitis
- Condition: Nonalcoholic Steatohepatitis
- Condition: Non-Alcoholic Fatty Liver Disease
- Intervention (Drug): MSDC-0602K
- Intervention (Drug): Placebo
- Lead sponsor: Cirius Therapeutics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Fatty liver disease (NAFLD / MASLD) (`cardio:nafld`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 3f64f18d83758f5424fab222acce834448815efc1bfb9aae6a8f13d7e009daf5
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
